The present disclosure provides novel compounds derived from docosahexaenoic acid endocannabinoid epoxides having anti-cancer, anti-inflammatory, anti-platelet aggregation and anti-angiogenic properties. Methods of synthesizing and using the compositions are also provided.

Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

The present invention relates to a carboxylic branched chain-cutting agent for a golf ball-covering ionomer resin, a golf ball coating composition, and a method for manufacturing a golf ball. The present invention can provide a coating composition containing within an appropriate range, a specific compound for use as a carboxylic branched chain-cutting agent for a golf ball-covering ionomer resin, and thus can provide a golf ball on which a bridge is formed between a golf ball covering resin and a coating resin. By providing the coating composition containing a specific composition for use as a carboxylic branched chain-cutting agent for a golf ball-covering ionomer resin, the present invention is appropriate for ensuring the physical properties of the golf ball, such as yellowing resistance, and workability, such as pot life, even eliminating an adhesion pretreatment step, thereby reducing side effects due to the existing pretreatment step while providing a golf ball having excellent physical properties.

The present invention relates to a carboxylic branched chain-cutting agent for a golf ball-covering ionomer resin, a golf ball coating composition, and a method for manufacturing a golf ball. The present invention can provide a coating composition containing within an appropriate range, a specific compound for use as a carboxylic branched chain-cutting agent for a golf ball-covering ionomer resin, and thus can provide a golf ball on which a bridge is formed between a golf ball covering resin and a coating resin. By providing the coating composition containing a specific composition for use as a carboxylic branched chain-cutting agent for a golf ball-covering ionomer resin, the present invention is appropriate for ensuring the physical properties of the golf ball, such as yellowing resistance, and workability, such as pot life, even eliminating an adhesion pretreatment step, thereby reducing side effects due to the existing pretreatment step while providing a golf ball having excellent physical properties.

The present specification relates to a (meth)acrylate compound, and a copolymer and a homopolymer including a repeating unit derived therefrom.

The present specification relates to a (meth)acrylate compound, and a copolymer and a homopolymer including a repeating unit derived therefrom.

The present disclosure provides chemical compound derivatives of a class of biological lipid mediators known as endocannabinoids and methods of synthesizing the compositions. These compounds are useful for treating cancer, reducing inflammation, reducing platelet aggregation, and reducing angiogenesis.

The present disclosure provides chemical compound derivatives of a class of biological lipid mediators known as endocannabinoids and methods of synthesizing the compositions. These compounds are useful for treating cancer, reducing inflammation, reducing platelet aggregation, and reducing angiogenesis.

The present invention relates to an aryl ethene derivative, for inhibiting an estrogen-related receptor gamma (ERRγ) activity, a prodrug of same, a solvate of same, a stereoisomer of same or pharmaceutically acceptable salts of same, and a pharmaceutical composition containing same as an active ingredient.